Combined Treatment of RFA and Sorafenib on Recurrent HCC

Summary

RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC. So the investigators hypothesized that combined RFA and Sorafenib might reduce the frequency of recurrence and improve the overall survival and disease free survial.

Conditions

• HCC
• Radiofrequency Ablation
• Sorafenib

Interventions

OTHER

RFA + Sorafenib

combined RFA and Sorafenib to treat recurrent HCC

OTHER

RFA

treat Recurrent HCC with RFA

Sponsors & Collaborators

• Hunan Province Tumor Hospital

  collaborator OTHER

• Tang-Du Hospital

  collaborator OTHER

• Xijing Hospital

  collaborator OTHER

• First Affiliated Hospital of Guangxi Medical University

  collaborator OTHER

• First Affiliated Hospital Xi'an Jiaotong University

  collaborator OTHER

• Anhui Provincial Hospital

  collaborator OTHER_GOV

• Xiangya Hospital of Central South University

  collaborator OTHER

• Xinqiao Hospital of Chongqing

  collaborator OTHER

• Xinjiang Tumor Hospital

  collaborator UNKNOWN

• People's Hospital of Guangxi Zhuang Autonomous Region

  collaborator OTHER

• Henan Cancer Hospital

  collaborator OTHER_GOV

• People's Hospital of Sichuan

  collaborator UNKNOWN

• Huaxi Hospital

  collaborator OTHER

• Southwest Hospital, China

  lead OTHER

Principal Investigators

• Kuansheng Ma, MD,Ph.D · Southwest Hopstial

Study Design

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-01-31

Primary Completion

2018-12-31

Completion

2018-12-31

Countries

• China

Study Locations